Investigating genetic and molecular factors in multiple sclerosis outcomes
Official title: From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
Run by Nantes University Hospital · NCT04873492 · Data updated 2026-11-12
This study is trying to find out how genetic and molecular differences in people with multiple sclerosis can explain why some have a more severe form of the disease than others.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 130 (estimated) |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 1 site (Nantes, Loire-Atlantique) |
| Status | Recruiting |
| Started | January 24, 2022 |
| Main results expected | July 24, 2029 |
| Study ends | July 24, 2029 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT04873492 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with clinical isolated syndrome, either aggressive or non-aggressive forms of multiple sclerosis.
✕Probably not a fit
Patients with a history of clinically isolated syndrome or multiple sclerosis who do not meet the inclusion criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to explore the genetic and transcriptomic differences in patients with multiple sclerosis (MS) to understand why some individuals experience aggressive disease progression while others do not. By analyzing biological samples from patients with clinical isolated syndrome, the research will focus on identifying differentially expressed molecules and cell subpopulations among aggressive and non-aggressive MS patients compared to healthy controls. The study will involve the collection of biological samples to facilitate these analyses, contributing to a better understanding of MS heterogeneity.
Why it matters
Potential benefit: If successful, this research could lead to improved personalized treatment strategies for patients with multiple sclerosis.
How similar studies have gone: While similar studies have explored genetic factors in MS, this specific approach focusing on transcriptomics and aggressive versus non-aggressive outcomes is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria : Common criteria for retrospective MS patients: * Patients aged 18 years or older * Clinical isolated syndrome (CIS) with or without dissemination in space * Patients affiliated to an appropriate health insurance Criteria for Aggressive MS group • Start of a 2nd line therapy within the two years following the CIS Criteria for Non aggressive MS group * No conversion according to McDonald criteria from clinical isolated syndrome to multiple sclerosis within 2 years or * Conversion based to McDonald criteria treated or not with first line disease modifying therapy within 2 years. * Have a minimum of least 2 years of follow-up. Healthy volunteers * Aged 18 years or older * No history of clinically isolated syndrome or MS Pairing criteria : * Age +/- 5 years * Sex Prospective MS Patients * Patients aged 18 years or older * Clinical isolated syndrome (CIS) with or without dissemination in space * Patients affiliated to an appropriate health insurance Exclusion Criteria : * Ongoing participation to a another study * Refusal to genetic analyses * Immunosuppressive drug at the time of blood collection * Plasma exchange or corticosteroid treatment within the four weeks prior to blood sample * Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard) * Pregnancy
Where it's running
-
Nantes University Hospital
Nantes, Loire-Atlantique, France Recruiting
Study contacts
- Study coordinator: David LAPLAUD, PhD
- Email: david.laplaud@chu-nantes.fr
- Phone: 33 2 40 16 52 00
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
-
Cooling During Inpatient Rehab for People with MS
This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.